MDM2-p53 antagonist (BI 907828): mechanism of action

BI 907828 is small molecule inhibiting the interaction between murine double minute 2 (MDM2) and p53. MDM2 is a negative regulator of the tumour suppressor p53. BI 907828 blocks the interaction between MDM2 and p53 by binding to free MDM2. This reactivates p53 tumour suppressor function and induction of target gene expression, leading to cell cycle arrest or apoptosis in tumours with wild-type p53. Our MDM2-p53 antagonist is currently undergoing clinical investigation as a monotherapy and in combination with a PD-1 inhibitor and a LAG-3 inhibitor in patients with solid tumours.

BI 907828 is an investigational compound and has not been approved. Its safety and efficacy has not been established.

To find out more about ongoing clinical trials in cancer please go to: https://www.mystudywindow.com/trials/...

Click on the red button above to subscribe to our YouTube channel.

Taking cancer on by directly targeting cancer cells is a fundamental treatment strategy. We are working to further unlock the power of cancer cell-directed therapies. Our focus, passion and commitment, combined with our strong collaborations, will help us transform expectations, give hope to more patients and help win the fight against cancer.

For more information about the currently enrolling Phase I studies of this compound, visit: https://www.mystudywindow.com/trial/l... and https://www.mystudywindow.com/trial/l....